MORGAN STANLEY PLC/CALL/AMGEN/290/0.1/20.12.24 | Market Closed - Börse Stuttgart 12:01:34 06/07/2024 am IST | ||
| 3.62 EUR | +3.13% |
|
| Current month | -3.72% | ||
| 1 month | -0.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 3.62 | +3.13% |
| 04/24/04 | 3.51 | -0.57% |
| 03/24/03 | 3.53 | -6.61% |
| 02/24/02 | 3.78 | +1.07% |
| 01/24/01 | 3.74 | -0.53% |
Delayed Quote Börse Stuttgart
Last update July 06, 2024 at 12:01 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MB16YL |
| ISIN | DE000MB16YL1 |
| Date issued | 05/12/2022 |
| Strike | 290 $ |
| Maturity | 20/12/2024 (167 Days) |
| Parity | 10 : 1 |
| Emission price | 4.91 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.03 € |
|---|---|
| Lowest since issue | 0.38 € |
| Spread | 0.03 € |
| Spread % | 0.82% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
310.9
USD
Average target price
316.4
USD
Spread / Average Target
+1.79%
- Stock Market
- Warrants
- Warrant
